



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 27-12-2010

Umme Salma
Assistant Director,
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT AND INDUSTRIAL
DESIGNS FOR THE WEEK-ENDING OF 11-12-2010 TO BE
PUBLISHED 30-12-2010 IN THE GAZETTE OF PAKISTAN PART-
V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

Sd/-

(Sabir Gul)

Controller of Patents
& Registrar of Designs
Ph: 99215056

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

06-12-2010

1000/2010	Novartis AG., Switzerland (Priority 07-12-2009 USA)	”Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof”
1001/2010	Sicpa Holding SA., Switzerland (Priority 08-12-2009 USA)	“Chiral liquid crystal polymer marking”
1002/2010	Sicpa Holding SA., Switzerland (Priority 08-12-2009 USA)	“Modified marking based on chiral liquid crystal polymers”
1003/2010	Sicpa Holding SA., Switzerland (Priority 08-12-2009 USA)	“ Marking based on chiral liquid crystal polymers”
1004/2010	Sicpa Holding SA., Switzerland (Priority 08-12-2009 USA)	“Marking based on modified chiral liquid crystal polymers”
1005/2010	Medivir AB., Sweden Tibotec Pharmaceuticals, Ireland (Priority 11-12-2009 Europe)	“5-amino-4-hydroxy-pentoyl amides”
1006/2010	Sanofi-Aventis, France (Priority 08-12-2009 Hungary)	“New process for the preparation of dronedarone”
1007/2010	Gaztransport ET Technigaz, France (Priority 09-12-2009 France)	“Tank for cryogenic fluid”
1008/2010	Targacept, INC., USA (Priority 07-12-2009 USA)	“3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands”

07-12-2010

1009/2010	Les Laboratoires Servier, France (Priority 09-12-2009 France)	“New azabicyclo[3.2.0]hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them”
1010/2010	Eli Lilly and Company, USA (Priority 21-12-2009 Europe)	“Mglu2 agonists”
1011/2010	Les Laboratoires Servier, France (Priority 09-12-2009 France)	“New compounds of the hexahydrocyclopenta[b]pyrrole type, a process for their preparation and pharmaceutical compositions containing them”
1012/2010	Les laboratoires Servier, France (Priority 09-12-2009 France)	“New azabicyclo[3.1.0]hex-2-yl compounds, a process for their preparation and pharmaceutical compositions containing them”
1013/2010	Les Laboratoires Servier, France (Priority 09-12-2009 France)	“New azabicyclo[3.2.0]hept-6-yl compounds, a rocess for their preparation and pharmaceutical compositions containing them”
1014/2010	Unilever PLC., United Kingdom (Priority 11-12-2009 China)	“Tea-based product”

08-12-2010

1015/2010	Sanofi-Aventis, France (Priority 10-12-2009 France)	“Disubstituted 9h-pyridino[3,4-b]indole derivatives, preparation thereof and therapeutic use thereof”
1016/2010	Sanofi-Aventis, France (Priority 10-12-2009 France)	“Trisubstituted derivatives of 9h-beta- carboline (or 9h-pyridino[3,4-b]indole), preparation thereof and therapeutic use thereof”
1017/2010	Bayer Bioscience N.V., Belgium (Priority 22-12-2009 Europe/USA)	“Herbicide tolerant plants”

1018/2010 Bayer CropScience AG., “Liquid formulations”
Germany
(Priority 23-12-2009 Europe)

09-12-2010

1019/2010 Janssen Pharmceutica N.V., “Substituted aminothiazolone indazoles as
Belgium estrogen related receptor-a modulators”
(Priority 18-12-2009 USA)

1020/2010 Glaxo Smith Kline LLC., “6-Amino-7,9-dihydro-8H-purin-8-one salt
USA and pharmaceutical composition
Divisional comprising thereof”

1021/2010 Respivert Limited, “herapeutic uses”
United Kingdom
(Priority 11-12-2009 G.B)

1022/2010 Eli Lilly and Company, “Oxyntomodulin peptide analogue”
USA
(Priority 22-12-2009 USA)

1023/2010 Eli Lilly and Company Oxyntomodulin peptide analogue
USA
(Priority 22-12-2009 USA)

1024/2010 Tetra, SIA Novel acetylsalicylic acid salts
Latvia

1025/2010 (1)Muhammad Arif, Process for the development of malted
(2)Dr. Javed Abbas Bangash, powdered drink
(3)Faizullah Khan,
(4)Mrs. Hamida Abid,
Peshawar,
Pakistan

10-12-2010

1026/2010 Chiesi Farmaceutici S.p.A., Antibiotic microparticles for inhalation
Italy
(Priority 14-12-2009 Europe)

1027/2010 Novozymes A/S., Use of AMPs for Treatment of
Denmark UTI/Cystitis
(Priority 11-12-2009 Europe)

1028/2010 Novartis AG., Pcsk9 antagonists
Switzerland
IRM LLC,
Bermuda
(Priority 11-12-2009 USA)

11-12-2010

1029/2010 Abbott GmbH & Co, KG., Carboxamide Compounds and their use as
Germany Calpain Inhibitors V
Abbott Laboratories
USA
(Priority 22-12-2009 USA)

1030/2010 Sanofi-Aventis, Novel (heterocycle-
France tetrahydropyridine)(piperazinyl)-1-
(Priority 14-12-2009 France) alkanone and (heterocycle-
dihydropyrrolidine)(piperazinyl)-1-
alkanone derivatives, and use thereof as
p75 inhibitor

1031/2010 Sanofi-Aventis, Novel (heterocycle-fused piperidine)-
France (piperazinyl)-1-alkanone derivatives or
(Priority 14-12-2009 France) (heterocycle-fused pyrrolidine)-
(piperazinyl)-1-alkanone derivatives and
use thereof as p75 inhibitors

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

809/2000 F. Hoffmann-La Roche AG., “A pharmaceutical composition containing
Switzerland at least one lipase inhibitor, at least one
surfactant and at least one dispersant.”

A61K9/00

141028

A pharmaceutical composition comprising at least one lipase inhibitor, at least one surfactant selected from the group consisting of vitamin E_(polyethylene glycol 1000)_succinate (TPGS), polyoxyethylene stearates, polyoxyethylene alkyl ethers, polyoxyethylene castor oils, polyglycolized glycerides and lecithins and mixtures thereof and at least one dispersant.

332/2005 Bayer Bioscience N.V., “Rice pollen-preferential promoter region”
Belgium

C12N 15/11

141029

Promoters from rice are provided, which promote transcription preferentially in microspores and/or pollen of plants, such as rice plants. More specifically, disclosed is a

pollen-preferential promoter region comprising a nucleotide sequence selected from the group consisting of:

- a) the nucleotide sequence of SEQ ID No 7 from the nucleotide at position 16 to the nucleotide at position 1126;
- b) the nucleotide sequence of SEQ ID No 7 from the nucleotide at position 16 to the nucleotide at position 940;
- c) the nucleotide sequence of SEQ ID No 7 from the nucleotide at position 231 to the nucleotide at position 932.

606/2005 Glaxo Group Limited,
United Kingdom

“A therapeutic antibody, method for its preparation and Pharmaceutical composition comprising thereof”

CO7K 16/24

141030

The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical composition comprising said antibodies and methods of manufacture are also disclosed.

949/2006 Auburn University,
USA

"N-halamine/quaternary ammonium polysiloxane"

CO84/77/388

141031

Precursor N-halamine/quaternary ammonium random copolymers which are soluble in water for the purpose of functionalizing surfaces or materials so as to render them biocidal upon exposure to oxidative halogen solutions. The biocidal function can be imparted to the precursor

N-halamine moiety either before or after siloxane bonding or adhesion to the surface or material. The biocidal surfaces and materials can then be used to inactivate pathogenic microorganisms such as bacteria, fungi, and yeasts, as well as virus particles, that can cause infectious diseases and those microorganisms that cause noxious odors and unpleasant coloring such as mildew. Examples of surfaces and materials which can be rendered biocidal include, but are not limited to, cellulose, chitin, chitosan, synthetic fibers, glass, ceramics, plastics, rubber, cement grout, latex caulk, porcelain, acrylic films, vinyl, polyurethanes, silicon tubing, marble, metals, metal oxides, and silica.


1020/2007 Glaxo Group Limited,
Great Britain

“N-{{[1,6-Diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide ;pharmaceutical composition comprising said compound”


CO7D 471/04, A61K 31/437, A61P 11/00,
A61P 19/00

141032

The invention provides a compound of NH formula (I):



wherein Ar has the sub-formula (x):



and wherein:

Q^1 is NH or NMe, in which case Q^2 is -C(O)-, -S(O)₂-, -C(O)NH- or -C(O)NMe-;

or Q^1 is a bond or -O-, in which case Q^2 is a bond;

or Q^1 is -C(O)-, in which case Q^2 is NH or NMe;

or Q^1 is -S(O)₂-, in which case Q^2 is NH, NMe or a bond;

and L is (CH₂)_n wherein n is 4 to 13; or L is -(CH₂)_m¹-O-(CH₂)_m²-.

and pharmaceutical composition comprising the compound for use in the treatment and/or prophylaxis of an inflammatory and/or allergic disease.


459/2008 Pfizer Limited,
United Kingdom

Aryl-substituted n-[6-amino-5-aryl-pyridin-2-yl]-carboxamide derivatives.

A61K 31/44, A61P 29/00, A61K 31/4427

141033

The present invention relates to compound of the formula (I):



process for the preparation of intermediate used in the preparation of, and composition

containing such compound and the uses of such compound for the treatment of pain.


682/2008 Sanofi-Aventis,
France

"Substituted 7-alkynyl-1,8-naphthyridone compound"

CO7D 471/04, A61K 31/4375

141034

The invention relates to 7-alkynyl-1,8-naphthyridone compound of formula (I):



in which R₁, R₂, R₃ and R₄ are as defined in the description, process for the preparation thereof and pharmaceutical composition comprising thereof.

888/2008 Shahina Fayyaz,
M.H. Soomro,
Tabassum Ara Khanum,
M. Ismail Bhatti,
National Nematological
Research Centre,
University of Karachi,
Pakistan

"A process of preparation of rearing diet for galleria Mellonella larvae, used for isolation and mass production of Beneficial organisms"

A23L1

141035

This invention relates to a process and preparation of rearing diet which provide an easy and cheaper diet for rearing of healthy wax moth larvae and long term storage (12-18 months) in dry oat at 12-15°C in plastic boxes. Galleria mellonella larvae used as a bait for isolation and mass production of entomopathogenic nematodes, which are used as bio-control agent of more than 300 pests of different crops.

1281/2008 Mcp Operations Pty Limited, Australia A tablet coating comprising a powdered flavour composition

A61K 9/30, A61K 9/36

141036

The present invention provides a tablet coating composition including a cellulose polymer, a plasticiser, a sweetener, and a powdered flavour composition. The powdered flavour composition includes a flavourant associated with a solid carrier. The present invention also provides a pharmaceutical tablet including a core containing an active agent and a coating formed from the tablet coating composition.


181/2009 Novartis AG., Switzerland


“Substituted pyridinyl-thiazole-4-carboxamide compound”

A61K 31/4439, A61P 35/00

141037

The present invention relates to new compound of Formulas I and II, composition of the new compound together with pharmaceutically acceptable carriers, and uses of the new compounds either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer






234/2009 Les Laboratories Servier,
France

“New diosmetin compound, a process for its preparation and pharmaceutical composition containing it”


CO7D 311/30, CO7D 407/12, A61K 3/352,
CO7H 15/26, A61P 9/12

141038

Compound of formula (I):



wherein R_1 , R_2 and R_3 , which may be the same or different, each represent a hydrogen atom or the group of formula (A):



and a pharmaceutical composition comprising thereof.

1071/2009 Eli Lilly and Company,
USA

3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine compound”

CO7D 487/04, A61K 31/5025, A61P 21/00

141039

The present invention provides 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine compound useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.

981/2010 Eli Lilly and Company,
USA

“A pharmaceutically acceptable salt of 3-(4-chloro-2-fluorobenzyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine compound”

CO7D 487/04, A61K 31/5025, A61P 25/00

141040

The present invention provides a pharmaceutically acceptable salt of 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine compound useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.


999/2010 Pfizer Limited,
United Kingdom

“Pharmaceutically acceptable salt or solvate
of aryl-substituted n-[6-amino-5-aryl-
pyridin-2-yl]-carboxamide derivatives”

A61K 31/44

141041

The present invention relates to
pharmaceutically acceptable salt or solvate
of compound of the formula (I):



to process for the preparation of
intermediates used in the preparation of
composition containing such compound and
the use of such compound for the treatment
of pain.

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Inventor
<u>06-12-2010</u>			
1)	15081	Package (Class-05)	Tetra Laval Holdings & Finance S.A.
2)	15082	Package (Class-05)	Tetra Laval Holdings & Finance S.A.
3)	15083	Package (Class-05)	Tetra Laval Holdings & Finance S.A.
<u>07-12-2010</u>			
4)	15084	Imam's Chopper (Class-01)	Syed Ali Imam Tirmizi
5)	15085	Imam's Hook (Class-01)	Syed Ali Imam Tirmizi
6)	15086	Footwear Outer Sole (Class-10)	M/s. Firhaj Footwear (Pvt.) Limited
7)	15087	Footwear Outer Sole (Class-10)	M/s. Firhaj Footwear (Pvt.) Limited
8)	15088	Footwear Outer Sole (Class-10)	M/s. Firhaj Footwear (Pvt.) Limited
9)	15089	Footwear Outer Sole (Class-10)	M/s. Firhaj Footwear (Pvt.) Limited
<u>11-12-2010</u>			
10)	15090	Half Blade (Class-01)	Shahzad Maher & Co

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Inventor
<u>06-12-2010</u>			
1)	14975	Bottle (Class-03)	Tropicana Products Inc
2)	14976	Bottle (Class-03)	Tropicana Products Inc
<u>08-12-2010</u>			
3)	14678	Hot Pot (Class-03)	Shoaibee Industries
<u>09-12-2010</u>			
4)	14985	Bottle (Class-03)	Tropicana Products Inc
5)	14986	Bottle (Class-03)	Tropicana Products Inc
<u>10-12-2010</u>			
6)	14915	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
7)	14916	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
8)	149951	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
9)	14952	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
10)	14953	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,

Sd/-
(SABIR GUL)
Controller of Patents
& Registrar of Designs
Ph: 99215056